



## Kura Oncology to Report Third Quarter 2024 Financial Results

October 31, 2024

SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2024 financial results after the close of U.S. financial markets on Thursday, November 7, 2024. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing (800) 225-9448 for domestic callers and (203) 518-9708 for international callers and entering the conference ID: KURAQ3. A live webcast and archived replay of the event will be available [here](#) or online from the investor relations section of the company website at [www.kuraoncology.com](http://www.kuraoncology.com).

### About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company's pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction, has received Breakthrough Therapy Designation for the treatment of relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). Kura has completed enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML (KOMET-001). The Company is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. Kura is evaluating KO-2806, a next-generation farnesyl transferase inhibitor (FTI), in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies (FIT-001). Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial in combination with apelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma (KURRENT-HN). For additional information, please visit Kura's website at [www.kuraoncology.com](http://www.kuraoncology.com) and follow us on [X](#) and [LinkedIn](#).

### Contacts

Investors:

Pete De Spain  
Executive Vice President, Investor Relations &  
Corporate Communications  
(858) 500-8833  
[pete@kuraoncology.com](mailto:pete@kuraoncology.com)

Media:

Cassidy McClain  
Vice President  
Inizio Evoke Comms  
(619) 849-6009  
[cassidy.mcclain@inizioevoke.com](mailto:cassidy.mcclain@inizioevoke.com)



Source: Kura Oncology, Inc.